Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer.

Knödler M, Körfer J, Kunzmann V, Trojan J, Daum S, Schenk M, Kullmann F, Schroll S, Behringer D, Stahl M, Al-Batran SE, Hacker U, Ibach S, Lindhofer H, Lordick F.

Br J Cancer. 2018 Aug;119(3):296-302. doi: 10.1038/s41416-018-0150-6. Epub 2018 Jul 10.

PMID:
29988111
2.

Immunotherapy with the trifunctional anti-CD20 × anti-CD3 antibody FBTA05 in a patient with relapsed t(8;14)-positive post-transplant lymphoproliferative disease.

Kieslich A, Ruf P, Lindhofer H, Buhmann R, Eggert A, Hundsdoerfer P.

Leuk Lymphoma. 2017 Aug;58(8):1989-1992. doi: 10.1080/10428194.2016.1272687. Epub 2017 Jan 16. No abstract available.

PMID:
28093004
3.

Potent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition.

Deppisch N, Ruf P, Eißler N, Lindhofer H, Mocikat R.

Oncotarget. 2017 Jan 17;8(3):4520-4529. doi: 10.18632/oncotarget.13888.

4.

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors.

Haense N, Atmaca A, Pauligk C, Steinmetz K, Marmé F, Haag GM, Rieger M, Ottmann OG, Ruf P, Lindhofer H, Al-Batran SE.

BMC Cancer. 2016 Jul 7;16:420. doi: 10.1186/s12885-016-2449-0.

5.

Efficacy and Tolerability of a GD2-Directed Trifunctional Bispecific Antibody in a Preclinical Model: Subcutaneous Administration Is Superior to Intravenous Delivery.

Deppisch N, Ruf P, Eissler N, Neff F, Buhmann R, Lindhofer H, Mocikat R.

Mol Cancer Ther. 2015 Aug;14(8):1877-83. doi: 10.1158/1535-7163.MCT-15-0156. Epub 2015 Jun 10.

6.

Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies.

Schuster FR, Stanglmaier M, Woessmann W, Winkler B, Siepermann M, Meisel R, Schlegel PG, Hess J, Lindhofer H, Borkhardt A, Buhmann R.

Br J Haematol. 2015 Apr;169(1):90-102. doi: 10.1111/bjh.13242. Epub 2014 Dec 11.

PMID:
25495919
7.

Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer.

Woopen H, Pietzner K, Richter R, Fotopoulou C, Joens T, Braicu EI, Mellstedt H, Mahner S, Lindhofer H, Darb-Esfahani S, Denkert C, Sehouli J.

J Gynecol Oncol. 2014 Jul;25(3):221-8. doi: 10.3802/jgo.2014.25.3.221. Epub 2014 Jul 3.

8.

The role of relative lymphocyte count as a biomarker for the effect of catumaxomab on survival in malignant ascites patients: results from a phase II/III study.

Heiss MM, Ströhlein MA, Bokemeyer C, Arnold D, Parsons SL, Seimetz D, Lindhofer H, Schulze E, Hennig M.

Clin Cancer Res. 2014 Jun 15;20(12):3348-57. doi: 10.1158/1078-0432.CCR-13-2351. Epub 2014 Apr 8.

9.

Expression of epithelial cell adhesion molecule in paired tumor samples of patients with primary and recurrent serous ovarian cancer.

Pietzner K, Woopen H, Richter R, Joens T, Braicu EI, Dimitrova D, Mellstedt H, Darb-Esfahani S, Denkert C, Lindhofer H, Fotopoulou C, Sehouli J.

Int J Gynecol Cancer. 2013 Jun;23(5):797-802. doi: 10.1097/IGC.0b013e3182929056.

PMID:
23694980
10.

Potential of the trifunctional bispecific antibody surek depends on dendritic cells: rationale for a new approach of tumor immunotherapy.

Eissler N, Mysliwietz J, Deppisch N, Ruf P, Lindhofer H, Mocikat R.

Mol Med. 2013 Apr 30;19:54-61. doi: 10.2119/molmed.2012.00140.

11.

Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model.

Ruf P, Schäfer B, Eissler N, Mocikat R, Hess J, Plöscher M, Wosch S, Suckstorff I, Zehetmeier C, Lindhofer H.

J Transl Med. 2012 Nov 7;10:219. doi: 10.1186/1479-5876-10-219.

12.

Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect.

Eissler N, Ruf P, Mysliwietz J, Lindhofer H, Mocikat R.

Cancer Res. 2012 Aug 15;72(16):3958-66. doi: 10.1158/0008-5472.CAN-12-0146. Epub 2012 Jun 28.

13.

Cancer therapy with trifunctional antibodies: linking innate and adaptive immunity.

Hess J, Ruf P, Lindhofer H.

Future Oncol. 2012 Jan;8(1):73-85. doi: 10.2217/fon.11.138. Review.

PMID:
22149036
14.

Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3).

Jäger M, Schoberth A, Ruf P, Hess J, Hennig M, Schmalfeldt B, Wimberger P, Ströhlein M, Theissen B, Heiss MM, Lindhofer H.

Cancer Res. 2012 Jan 1;72(1):24-32. doi: 10.1158/0008-5472.CAN-11-2235. Epub 2011 Nov 1.

15.

Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites.

Ott MG, Marmé F, Moldenhauer G, Lindhofer H, Hennig M, Spannagl R, Essing MM, Linke R, Seimetz D.

Int J Cancer. 2012 May 1;130(9):2195-203. doi: 10.1002/ijc.26258. Epub 2011 Sep 27.

16.

First patient treated with a re-challenge of catumaxomab in recurrent malignant ascites: a case report.

Pietzner K, Jäger M, Schoberth A, Oskay-Özcelik G, Kuhberg M, Lindhofer H, Sehouli J.

Med Oncol. 2012 Jun;29(2):1391-6. doi: 10.1007/s12032-011-9961-5. Epub 2011 May 5.

PMID:
21544631
17.

Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial.

Ströhlein MA, Lordick F, Rüttinger D, Grützner KU, Schemanski OC, Jäger M, Lindhofer H, Hennig M, Jauch KW, Peschel C, Heiss MM.

Onkologie. 2011;34(3):101-8. doi: 10.1159/000324667. Epub 2011 Feb 18.

PMID:
21358214
18.

Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients.

Ruf P, Kluge M, Jäger M, Burges A, Volovat C, Heiss MM, Hess J, Wimberger P, Brandt B, Lindhofer H.

Br J Clin Pharmacol. 2010 Jun;69(6):617-25. doi: 10.1111/j.1365-2125.2010.03635.x.

19.

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.

Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, Ganea-Motan E, Ciuleanu T, Wimberger P, Schmittel A, Schmalfeldt B, Burges A, Bokemeyer C, Lindhofer H, Lahr A, Parsons SL.

Int J Cancer. 2010 Nov 1;127(9):2209-21. doi: 10.1002/ijc.25423.

20.

Structural and functional characterization of the trifunctional antibody catumaxomab.

Chelius D, Ruf P, Gruber P, Plöscher M, Liedtke R, Gansberger E, Hess J, Wasiliu M, Lindhofer H.

MAbs. 2010 May-Jun;2(3):309-19. Epub 2010 May 16.

21.

Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy.

Seimetz D, Lindhofer H, Bokemeyer C.

Cancer Treat Rev. 2010 Oct;36(6):458-67. doi: 10.1016/j.ctrv.2010.03.001. Epub 2010 Mar 27. Review.

PMID:
20347527
22.

Identification and characterization of oxidation and deamidation sites in monoclonal rat/mouse hybrid antibodies.

Timm V, Gruber P, Wasiliu M, Lindhofer H, Chelius D.

J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Mar 15;878(9-10):777-84. doi: 10.1016/j.jchromb.2010.01.036. Epub 2010 Jan 29.

PMID:
20153988
23.

Influence of catumaxomab on tumor cells in bone marrow and blood in ovarian cancer.

Wimberger P, Heubner M, Lindhofer H, Jäger M, Kimmig R, Kasimir-Bauer S.

Anticancer Res. 2009 May;29(5):1787-91.

24.

The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2.

Jäger M, Schoberth A, Ruf P, Hess J, Lindhofer H.

Cancer Res. 2009 May 15;69(10):4270-6. doi: 10.1158/0008-5472.CAN-08-2861. Epub 2009 May 12.

25.

Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study.

Sebastian M, Kiewe P, Schuette W, Brust D, Peschel C, Schneller F, Rühle KH, Nilius G, Ewert R, Lodziewski S, Passlick B, Sienel W, Wiewrodt R, Jäger M, Lindhofer H, Friccius-Quecke H, Schmittel A.

J Immunother. 2009 Feb-Mar;32(2):195-202. doi: 10.1097/CJI.0b013e318195b5bb.

PMID:
19238019
26.

Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis.

Ströhlein MA, Siegel R, Jäger M, Lindhofer H, Jauch KW, Heiss MM.

J Exp Clin Cancer Res. 2009 Feb 14;28:18. doi: 10.1186/1756-9966-28-18.

27.

Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion.

Buhmann R, Simoes B, Stanglmaier M, Yang T, Faltin M, Bund D, Lindhofer H, Kolb HJ.

Bone Marrow Transplant. 2009 Mar;43(5):383-97. doi: 10.1038/bmt.2008.323. Epub 2008 Oct 13.

PMID:
18850012
28.

Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels.

Stanglmaier M, Faltin M, Ruf P, Bodenhausen A, Schröder P, Lindhofer H.

Int J Cancer. 2008 Sep 1;123(5):1181-9. doi: 10.1002/ijc.23626.

29.

Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody.

Morecki S, Lindhofer H, Yacovlev E, Gelfand Y, Ruf P, Slavin S.

Exp Hematol. 2008 Aug;36(8):997-1003. doi: 10.1016/j.exphem.2008.03.005. Epub 2008 May 20.

PMID:
18495330
30.

Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer.

Ruf P, Gires O, Jäger M, Fellinger K, Atz J, Lindhofer H.

Br J Cancer. 2007 Aug 6;97(3):315-21. Epub 2007 Jul 10.

31.

Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.

Burges A, Wimberger P, Kümper C, Gorbounova V, Sommer H, Schmalfeldt B, Pfisterer J, Lichinitser M, Makhson A, Moiseyenko V, Lahr A, Schulze E, Jäger M, Ströhlein MA, Heiss MM, Gottwald T, Lindhofer H, Kimmig R.

Clin Cancer Res. 2007 Jul 1;13(13):3899-905.

32.

Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study.

Sebastian M, Passlick B, Friccius-Quecke H, Jäger M, Lindhofer H, Kanniess F, Wiewrodt R, Thiel E, Buhl R, Schmittel A.

Cancer Immunol Immunother. 2007 Oct;56(10):1637-44. Epub 2007 Apr 5.

PMID:
17410361
33.

Biodistribution and radioimmunotherapy of SCCHN in xenotransplantated SCID mice with a 131I-labelled anti-EpCAM monoclonal antibody.

Andratschke M, Gildehaus FJ, Johannson V, Schmitt B, Mack B, Reisbach G, Lang S, Lindhofer H, Zeidler R, Wollenberg B, Luebbers CW.

Anticancer Res. 2007 Jan-Feb;27(1A):431-6.

34.

EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges.

Chaudry MA, Sales K, Ruf P, Lindhofer H, Winslet MC.

Br J Cancer. 2007 Apr 10;96(7):1013-9. Epub 2007 Feb 27. Review.

35.

Increased chondroitin sulphate proteoglycan expression (B5 immunoreactivity) in metastases of uveal melanoma.

Kiewe P, Bechrakis NE, Schmittel A, Ruf P, Lindhofer H, Thiel E, Nagorsen D.

Ann Oncol. 2006 Dec;17(12):1830-4. Epub 2006 Sep 13.

PMID:
16971663
36.

Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer.

Kiewe P, Hasmüller S, Kahlert S, Heinrigs M, Rack B, Marmé A, Korfel A, Jäger M, Lindhofer H, Sommer H, Thiel E, Untch M.

Clin Cancer Res. 2006 May 15;12(10):3085-91.

37.

Prednisolone reduces TNF-alpha release by PBMCs activated with a trifunctional bispecific antibody but not their anti-tumor activity.

Walz A, Andratschke M, Wollenberg B, Lindhofer H, Zeidler R.

Anticancer Res. 2005 Nov-Dec;25(6B):4239-43.

38.

Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes.

Morecki S, Lindhofer H, Yacovlev E, Gelfand Y, Slavin S.

Blood. 2006 Feb 15;107(4):1564-9. Epub 2005 Oct 18.

39.

Lasting remission following multimodal treatment in a patient with metastatic breast cancer.

Stemmler HJ, Menzel H, Salat C, Lindhofer H, Kahlert S, Heinemann V, Kolb HJ.

Anticancer Drugs. 2005 Nov;16(10):1135-7.

PMID:
16222157
40.

Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot study.

Stemmler HJ, Salat C, Lindhofer H, Menzel H, Untch M, Kahlert S, Konecny G, Sauer H, Ledderose G, Heinemann V, Kolb HJ.

Anticancer Res. 2005 Jul-Aug;25(4):3047-54.

41.

Immunotherapy of malignant ascites with trifunctional antibodies.

Heiss MM, Ströhlein MA, Jäger M, Kimmig R, Burges A, Schoberth A, Jauch KW, Schildberg FW, Lindhofer H.

Int J Cancer. 2005 Nov 10;117(3):435-43.

42.

Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes.

Schmitt M, Schmitt A, Reinhardt P, Thess B, Manfras B, Lindhofer H, Riechelmann H, Wiesneth M, Gronau S.

Int J Oncol. 2004 Oct;25(4):841-8.

PMID:
15375531
43.

Two new trifunctional antibodies for the therapy of human malignant melanoma.

Ruf P, Jäger M, Ellwart J, Wosch S, Kusterer E, Lindhofer H.

Int J Cancer. 2004 Feb 20;108(5):725-32.

44.

TNFalpha contributes to the antitumor activity of a bispecific, trifunctional antibody.

Zeidler R, Mayer A, Gires O, Schmitt B, Mack B, Lindhofer H, Wollenberg B, Walz A.

Anticancer Res. 2001 Sep-Oct;21(5):3499-503.

PMID:
11848515
45.

Impact of the lymphoma idiotype on in vivo tumor protection in a vaccination model based on targeting antigens to antigen-presenting cells.

Kronenberger K, Dieckmann A, Selmayr M, Strehl J, Wahl U, Lindhofer H, Kraal G, Mocikat R.

Blood. 2002 Feb 15;99(4):1327-31.

46.
47.

Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3).

Riesenberg R, Buchner A, Pohla H, Lindhofer H.

J Histochem Cytochem. 2001 Jul;49(7):911-7.

PMID:
11410615
48.

The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells.

Zeidler R, Mysliwietz J, Csánady M, Walz A, Ziegler I, Schmitt B, Wollenberg B, Lindhofer H.

Br J Cancer. 2000 Jul;83(2):261-6.

49.

Gene therapy of B-cell lymphoma with cytokine gene-modified trioma cells.

Strehl J, Selmayr M, Kremer JP, Hültner L, Lindhofer H, Mocikat R.

Int J Cancer. 1999 Sep 24;83(1):113-20.

50.

Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing.

Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, Lindhofer H.

J Immunol. 1999 Aug 1;163(3):1246-52.

Supplemental Content

Loading ...
Support Center